Monitoring Osteoporosis Therapy With Bone Densitometry: Misleading Changes and Regression to the Mean

Article Abstract:

Doctors should not discontinue alendronate or raloxifene if women who take either drug lose bone mass. Both drugs are used by postmenopausal women to prevent bone loss. Researchers analyzed data from two studies of over 6,000 postmenopausal women, some of whom took alendronate, some of whom took raloxifene, and some of whom took a placebo. Women who lost bone during the first year of treatment were likely to gain bone mass during the second year. Conversely, women who gained bone mass the first year often lost bone mass the second year.

Osteoporosis, Alendronate

---

Phytoestrogen supplements for the treatment of hot flashes: a randomized controlled trial

Article Abstract:

Two alternative treatments for menopause may not be very effective, according to a study of 246 women who kept a daily diary during the study. Neither Promensil nor Rimostil was any better than a placebo, or inactive substance, in reducing the number of hot flashes. Both of these products contain red clover, which is a source of isoflavones.

Care and treatment, Product/Service Evaluation, Menopause, Promensil (Dietary supplement), Rimostil (Dietary supplement)

---

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial

Article Abstract:

The drug raloxifene appears to lower the risk of breast cancer in postmenopausal women. Raloxifene has properties that mimic estrogen or block the action of estrogen depending on the organ. Researchers randomly assigned 7,705 postmenopausal women to take raloxifene or a placebo and then followed the women for at least three years. The drug was used to prevent bone fractures because all the women had osteoporosis. After three years, raloxifene reduced the risk of breast cancer by 76%.

Breast cancer

Similar abstracts:

• Abstracts: Effect of Estrogen on Brain Activation Patterns in Postmenopausal Women During Working Memory Tasks. Estrogen and Alzheimer Disease Plausible Theory, Negative Clinical Trial
• Abstracts: Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: A randomized clinical trial. (ORIGINAL CONTRIBUTION)
• Abstracts: Dietary patterns in six European populations: Results from EURALIM, a collaborative European data harmonization and information campaign

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.